Crowds flock to Brighton as UK issues amber heat alert
:: June 19, 2025
:: The health agency warned of possible extra risks for those over 65 or with health conditions
:: Brighton, England
The UK Health Security Agency (UKHSA) and the Met Office have issued an amber heat-health alert, meaning weather with health impacts across wider population.
The agency also warned of possible "increase in risk to health for individuals aged over 65 years or those with pre-existing health conditions."
Temperatures across the country are expected to rise until the end of the week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Thunderstorm warnings issued for parts of the country amid ongoing heatwave
Weather warnings have been issued for thunderstorms across parts of Scotland and Northern Ireland as the fourth heatwave of the summer continues. The Met Office has issued a yellow thunderstorm warning for large part of north-eastern Scotland, where it said up to 70mm of rain could fall in two hours. A yellow thunderstorm warning has also been issued for the eastern part of Northern Ireland, which could see up to 50mm of rain. Flood alerts have also been issued for Scotland. In both areas the Met Office has warned of difficult driving conditions and possible disruption to public transport and power supplies, and of a risk of flooding to homes and businesses. The forecaster also said fast-flowing or deep floodwater could pose a danger to life. Both yellow thunderstorm warnings are in place until 10pm on Thursday. It comes as heat health alerts were extended into next week for much of England. The UK Health Security Agency said yellow warnings will now be in place for Yorkshire and Humber, the East and West Midlands, London and the South East, South West and east of England until 6pm on August 18. The Scottish Environment Protection Agency said heavy thundery showers or rain may affect the region on Thursday, with a risk of significant localised flooding from surface water and smaller rivers. Heavy rain and thunder hit London and Kent on Wednesday. But officials have said England is suffering from 'nationally significant' water shortfalls. The national drought group, which includes the Met Office, regulators, government, water companies and other organisations, has met as five areas of the country remain in drought, with six more in prolonged dry weather status. On Thursday there will be residual showers and isolated thunderstorms across the South East, gradually clearing, and lightning, hail and heavy rain drifting northwards from Scotland into the Northern Isles. Paul Gundersen, chief meteorologist at the Met Office, said: 'Some areas will continue to experience their fourth heatwave of the summer so far, with Thursday remaining warm or very warm for many, though cooler near coasts. 'Temperatures could still reach 30C in eastern England, though many areas will be a few degrees cooler than earlier in the week.' Northern England will have patchy rain and cloud on Friday while southern England will enjoy sunshine and temperatures of up to 31C. The weekend should be dry and sunny for most parts of the UK, climbing to 30C on Saturday and 29C on Sunday in south-west England.
Medscape
7 minutes ago
- Medscape
Drug Combinations for CVDs Tied to Bullous Pemphigoid Risk
TOPLINE: A case-control study revealed that combinations of drugs for cardiovascular diseases and hypertension were frequently prescribed before a diagnosis of bullous pemphigoid (BP), but the risk associated with combinations did not exceed that associated with individual agents. The most common drug combinations included angiotensin-converting enzyme (ACE) inhibitors with statins and antiplatelets with statins. METHODOLOGY: Researchers conducted a nested case-control study using healthcare records from the Clinical Practice Research Datalink between 1998 and 2021 and analysed 16,844 BP cases and 79,493 age- and sex-matched control individuals having no BP diagnosis at the index date (the first date a BP diagnosis code was recorded). Association rule mining (ARM) identified the 10 most common drug class or active substance pairs prescribed to cases or control individuals on the same day and within 6 months before the index date. In the sensitivity analysis, researchers identified medication pairs prescribed within 30 days of each other and during the 6 months preceding the index date. Researchers quantified how often two drugs are co-prescribed compared with their independent prescribing by calculating a lift. They then derived the fold change (FC) as the ratio of a lift in cases vs control individuals. The analysis included multivariable conditional logistic regression to estimate the risk for BP following drug combinations and their constituent drugs. TAKEAWAY: The most frequent drug combinations associated with an increased risk for BP were ACE inhibitors-statins (FC of the lifts in the main analysis vs sensitivity analysis: 1.31 vs 1.18), antiplatelets-statins (1.23 vs 1.11), proton pump inhibitors (PPI)-antiplatelets (1.22 vs 1.14), PPI-statins (1.22 vs 1.14), and ACE inhibitors-antiplatelets (1.20 vs 1.09). For drug substances, combinations with a greater lift in BP cases were simvastatin-ramipril (FC, 1.30), simvastatin-aspirin (FC, 1.21), and ramipril-aspirin (FC, 1.19). After adjusting for BP-associated drugs, the Charlson Comorbidity Index, and relevant confounders, the increased risk remained significant for these drug class combinations: antiplatelets-statins (odds ratio [OR], 1.20), ACE inhibitors-statins (OR, 1.16), PPI-statins (OR, 1.22), ACE inhibitors-antiplatelets (OR, 1.26), and PPI-antiplatelets (OR, 1.43; P < .001 for all). The risk for BP associated with these frequently prescribed drug combinations was lower than the risk linked to each constituent drug at both class and substance levels. In both main and sensitivity analyses, patients who developed BP were more likely than control individuals to have received combinations of cardiovascular or antihypertensive drugs before diagnosis. IN PRACTICE: "The ARM algorithm exploratory analysis identified the most commonly prescribed drug combinations prior to BP. Logistic regression confirmed drug combinations for CVDs [cardiovascular diseases] or hypertension associated with increased BP risk," the authors wrote. "The increased BP risk following reported combinations was modest and was not greater than their constituent drugs. Given that the number of patients with BP is low, we do not suggest avoiding the reported drugs but instead being on the lookout for any skin reactions following treatments for CVDs or hypertension," they concluded. SOURCE: This study was led by Mikolaj Swiderski, University of Nottingham, Nottingham, England. It was published online on August 06, 2025, in Clinical and Experimental Dermatology. LIMITATIONS: The ARM algorithm considered only the frequency of prescriptions to obtain drug combinations. Additionally, the algorithm demonstrated limited clinical value, linking only half of the inferred drug class combinations with BP and failing to capture the sequence or precise timing of prescriptions. It also lacked dosage and treatment duration data, and as an exploratory tool, ARM could not establish causal relationships between drug exposures and the risk for BP. DISCLOSURES: This research was supported by the National Institute for Health and Care Research grant via the Research for Patient Benefit Programme. Swiderski reported receiving salary funding from this grant. Another author reported receiving salary funding from King's College London, University of Nottingham, and the National Institute for Health and Care Research East Midlands scholarship scheme. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
7 minutes ago
- Medscape
A1c Testing in EDs Can Spot Undiagnosed Diabetes Cases
TOPLINE: Among adults aged 30 years or older presenting to the emergency department (ED) without a prior diagnosis of type 2 diabetes (T2D), A1c testing combined with the Finnish Diabetes Risk Score (FINDRISC) identified a substantial proportion with prediabetes or diabetes — especially among those from ethnically diverse populations. METHODOLOGY: Researchers in England conducted a prospective study from December 2021 to December 2022 to determine the prevalence of glucose intolerance among 1382 individuals aged 30 years or older (45.1% men) who did not have a known diagnosis of diabetes and presented to the ED of a hospital in Manchester. They also tested the utility of the FINDRISC in predicting the risk for diabetes in high-risk individuals. Data on demographics, lifestyle factors, physical measurements, and A1c levels were collected, and the FINDRISC assessment was conducted by trained staff. Patients were classified as those having normal glucose tolerance, prediabetes, or diabetes according to both National Institute for Health and Care Excellence (NICE) and American Diabetes Association (ADA) guidelines. TAKEAWAY: On the basis of the NICE criteria, 80.1% of attendees had normal glucose tolerance, 11.6% had prediabetes, and 8.3% had diabetes; on the basis of the ADA criteria, the corresponding percentages were 61.3%, 30.4%, and 8.3%, respectively. Each unit increase in the FINDRISC was linked to an 8% (5%-12%) higher risk for prediabetes and a 16% (10%-23%) higher risk for diabetes, as per the NICE criteria, with similar findings seen for the ADA criteria as well; the risk remained elevated even after adjustment for confounders. Compared with White individuals, British South Asian and other minority groups showed nearly twice the risk for prediabetes (relative risk ratio [RRR], 1.94; 95% CI, 1.11-3.38) and three times the risk for diabetes (RRR, 2.80; 95% CI, 1.61-4.84). IN PRACTICE: "The considerable prevalence of undiagnosed diabetes within our patient population highlights the critical need for routine HbA1c screening in this setting, which may be the only place where hard-to-reach individuals may attend for healthcare," the authors wrote. SOURCE: This study was led by Edward B. Jude, Tameside and Glossop Integrated Care, NHS Foundation Trust, Manchester, England. It was published online on August 06, 2025, in Diabetes Therapy. LIMITATIONS: The accuracy of A1c testing can be affected by conditions altering the quality or quantity of haemoglobin, such as anaemia or haemoglobinopathies, potentially leading to an underestimation of diabetes prevalence. Selection bias may exist as the study focused only on patients who underwent bloodwork in the ED. The single-centre nature of the study limited the generalisability of the results. DISCLOSURES: This study received partial funding from Sanofi Pharmaceuticals and Novo Nordisk. One author was supported by the 4Ward North Wellcome Trust Clinical Research Training Fellowship, and another author declared receiving travel and research grants from the funding agencies and other sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
